证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-024 迪瑞医疗科技股份有限公司 第六届董事会第二次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第二次临时 会议（以下简称"本次会议"）于 2025 年 7 月 21 日在公司以现场结合通讯方式 召开，董事长宋清先生出差以通讯方式参加无法主持本次会议，经半数以上董事 推举，本次会议由董事倪冰先生主持。应出席公司会议的董事 9 人，实际出席公 司会议的董事 9 人，公司监事、高级管理人员列席会议。根据《公司章程》的规 定，本次会议通知于 2025 年 7 月 18 日以现场及电子邮件送达方式发出，会议召 开符合《中华人民共和国公司法》、《公司章程》的规定，会议合法有效。 二、会议审议情况 与会董事经认真审议，以现场结合通讯表决方式审议通过了如下决议： 1、审议并一致通过《关于变更公司董事的议案》 公司于近日收到控股股东深圳市华德欣润股权投资企业（有限合伙）及持股 5%以上股东广东恒健国际投资有限公司的通知 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-030 迪瑞医疗科技股份有限公司 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注：本公告格式中的"万元"均指人民币万元； 二、与会计师事务所沟通情况 一、本期业绩预计情况 （一）业绩预告期间 2025年1月1日至2025年6月30日。 （二）业绩预告情况：预计净利润为负值 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的 净利润 | 亏损：2,200万元-3,300万元 | 盈利：16,524.30万元 | | 扣除非经常性损益后的 净利润 | 亏损：2,600万元-3,900万元 | 盈利：16,236.33万元 | 特此公告！ 本次业绩预告数据仅为公司财务部门初步核算的结果，未经会计师事务所审 计。公司就本次业绩预告有关事项已与拟续聘的会计师事务所进行了预沟通，公 司与会计师事务所在本报告期的业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1. 受市场因素及行业政策不断深入的影响，公司总体毛利下降， ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Di Rui Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - Di Rui Medical's closing stock price is 14.28 yuan, with a PE ratio of 108.77, which is substantially higher than the industry average of 51.83 and the median of 37.23 [1][2] - The total market capitalization of Di Rui Medical is 3.894 billion yuan, ranking it 107th in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, five institutions hold shares in Di Rui Medical, with a total of 115.7415 million shares valued at 1.690 billion yuan [1] - The company specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with a total of 213 patents, including 136 invention patents [1] - The latest financial results show that Di Rui Medical achieved an operating income of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13%, with a gross profit margin of 42.78% [1]

Group 1 - The A-share medical device sector experienced a short-term surge, with Baolait rising over 17% [1] - Other stocks such as Jinan Development, Yangpu Medical, Tianyi Medical, Diri Medical, Guanhao Biological, and Chunli Medical also saw increases [1] - The rise in stock prices is attributed to the Chinese government's procurement measures affecting medical devices imported from the European Union [1]

Company Overview - Dirui Medical's closing price on July 4 was 14.03 yuan, down 1.06%, with a rolling PE ratio of 106.87 times and a total market capitalization of 3.826 billion yuan [1] - The company ranks 106th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1][2] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, and blood cell analysis [1] Financial Performance - In the first quarter of 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1] - The company holds 213 patents, including 136 invention patents and 96 software copyrights [1] Market Activity - On July 4, Dirui Medical experienced a net outflow of 1.1247 million yuan in principal funds, although the overall trend over the past five days showed a net inflow of 9.9255 million yuan [1]

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Dirui Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - Dirui Medical's closing stock price is 13.61 yuan, with a PE ratio of 103.67, which is substantially higher than the industry average of 49.45 and the median of 35.92 [1][2] - The company has a total market capitalization of 3.711 billion yuan, ranking 106th in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, five institutions hold shares in Dirui Medical, with a total of 115.7415 million shares valued at 1.690 billion yuan [1] - The main business of Dirui Medical includes the research, production, marketing, and service of medical testing instruments and related reagents, with a total of 213 patents, including 136 invention patents [1] - The latest quarterly report shows that the company achieved an operating income of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, a year-on-year decrease of 87.13%, with a gross profit margin of 42.78% [1]

Core Viewpoint - The stock of Dirui Medical closed at 13.78 yuan, marking a 1.62% increase, with a rolling PE ratio of 104.96, the lowest in 39 days, and a total market capitalization of 3.758 billion yuan [1] Company Summary - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related test strips and reagents [1] - The company has a total of 213 patents, including 136 invention patents, and has obtained 96 software copyrights [1] - For Q1 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13%, with a gross profit margin of 42.78% [1] Industry Summary - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, placing Dirui Medical at 107th in the industry ranking [2] - The static PE ratio for Dirui Medical is 26.48, and the price-to-book ratio is 1.82 [2] - The total market capitalization of Dirui Medical is 3.758 billion yuan, compared to the industry average market capitalization of 10.836 billion yuan [2]

Group 1: Company Performance and Strategy - In Q1 2025, the company installed over 400 high-speed instruments in the domestic market, improving reagent sales ratio through optimized sales structure [2] - The company adjusted its international sales strategy, focusing on Southeast Asia and Belt and Road countries, with minimal impact from uncontrollable factors [2] - The management aims to enhance reagent sales, reduce costs, and improve operational efficiency in response to performance challenges [2] Group 2: Profit Distribution and Shareholder Returns - The profit distribution plan for 2024 involves a cash dividend of RMB 2.60 per 10 shares, based on a total share capital of 272,700,161 shares, implemented on May 20, 2025 [3] - The company emphasizes long-term development while balancing short-term profit distribution to enhance investor returns [3] Group 3: Cost Reduction and Efficiency Improvement - The company is implementing measures to reduce costs and improve efficiency, including strengthening internal management and optimizing financial controls [4] - Ongoing efforts are focused on enhancing risk management capabilities to ensure sustainable profitability [4] Group 4: Research and Development Investments - The company is committed to R&D innovation, launching competitive products like the CS-690 automatic urine biochemical analyzer and CM-640 automatic chemiluminescence immunoassay analyzer [5][6] - R&D efforts are aligned with market trends, particularly in smart medical technology, enhancing the company's innovation capabilities [5][6] Group 5: Future Performance Improvement Measures - The company will focus on increasing reagent sales, improving accounts receivable, cash flow, and inventory management, while implementing a four-dimensional management approach [7] - The management is dedicated to ensuring stable and healthy company development [7] Group 6: Market Trends and Challenges - The in vitro diagnostic industry is driven by aging populations, domestic substitution, and new medical infrastructure, presenting opportunities for market share growth [9] - The company has established competitive advantages through over 30 years of independent R&D and has expanded its products to over 120 countries [9] Group 7: Market Value Management - The company has established a market value management system linked to executive performance evaluations, recognizing the importance of market performance for shareholder value [8] - The company plans to regularly review and adjust its market value management strategies in response to market conditions [8]

Company Overview - Dirui Medical's closing price on May 26 was 13.33 yuan, down 1.48%, with a rolling PE ratio of 101.54 times and a total market value of 3.635 billion yuan [1] - The company ranks 107th in the medical device industry, which has an average PE ratio of 48.92 times and a median of 35.68 times [1][2] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, chemiluminescence immunoassay, gynecological secretion analysis, blood cell analysis, coagulation analysis, and overall laboratory solutions [1] Financial Performance - In the first quarter of 2025, Dirui Medical reported operating revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1] - Over the past five days, the company experienced a net outflow of main funds amounting to 677,700 yuan, totaling 5.8154 million yuan in outflows [1]